ANeuroTech

Executive Summary

ANeuroTech is a Belgian biopharmaceutical company focused on addressing the unmet medical need of Partial Responsive Depression (PRD), a condition where patients experience inadequate response to initial antidepressant therapy. The company's lead candidate, ANT01, is an orally-administered small molecule designed to target subjective cognitive decline and potentiate the effects of standard antidepressants. ANT01 acts as a highly selective serotonin 2A antagonist, offering a unique mechanism that differentiates it from existing treatments. PRD affects a significant portion of depressed patients, and ANT01 aims to fill a critical gap in the therapeutic landscape by providing an adjunctive treatment that improves cognitive function and overall response rates. ANT01 is currently in late-stage Phase III development. The ongoing pivotal trial is expected to generate top-line data within the next year. If successful, ANT01 could become a key adjunctive therapy for PRD, potentially improving outcomes for millions of patients worldwide. ANeuroTech is privately held and has not disclosed funding details, but the advancement of ANT01 to Phase III suggests strong preclinical and early clinical data. The company may seek strategic partnerships or licensing deals to support commercialization. Given the high unmet need and differentiated mechanism, ANT01 represents a promising opportunity in the CNS space, though Phase III data and regulatory approval remain critical milestones.

Upcoming Catalysts (preview)

• Q1 2027Top-line results from Phase III trial of ANT01 in PRD60% success
• Q2 2027Regulatory submission for ANT01 in PRD (if positive data)50% success
• TBDOut-licensing or partnership deal for ANT0130% success